Health and Economic Outcomes of Pembrolizumab in the Treatment of Metastatic Non-small Cell Lung Cancer (mNSCLC) and Melanoma in Italy
The analysis demonstrated that, compared with chemotherapy, pembrolizumab is more cost effective in Italy as a first-line treatment in patients with metastatic squamous or non-squamous NSCLC and, if compared with watchful waiting, as adjuvant treatment in patients with stage III melanoma. The present analysis suggested that pembrolizumab use could lead to important health benefits for patients while offsetting a portion of cancer care costs.
Authors
- Francesco Saverio Mennini (ORCID: https://orcid.org/0000-0002-4738-5505)
- Chiara Bini (ORCID: https://orcid.org/0000-0001-5704-6542)
- Andrea Marcellusi (ORCID: https://orcid.org/0000-0002-3974-3798)
- Martina Paoletti (ORCID: https://orcid.org/0000-0002-2564-6698)
Institutions
- University of Rome Tor Vergata (IT)
- Kingston University London (GB)
Publication Details
- Journal
- Clinical Drug Investigation
- Published
- 2024-08-01
- DOI
- https://doi.org/10.1007/s40261-024-01366-y
- Citations
- 1
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.28
Funders
- Università degli Studi di Roma Tor Vergata